Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | MIF | P14174 | 2/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28065277 | 0.79 | ESR2 (0.45) | ADORA3ADORA2AADORA1XDHMAPT | |
| SCHEMBL27598165 | 0.73 | ERN1 (0.64) | APPALOX5ERN1MAPT | |
| SCHEMBL29679522 | 0.73 | ERN1 (0.64) | APPALOX5ERN1MAPT | |
| SCHEMBL812897 | 0.72 | CTRC (0.48) | MAPT | |
| SCHEMBL2398844 | 0.71 | KEAP1 (0.44) | MIFXDHMAPT | |
| SCHEMBL6689631 | 0.70 | GSTP1 (0.48) | MAPT | |
| SCHEMBL28742545 | 0.70 | APP (0.82) | APPADORA3ADORA2AADORA1ALOX5 | |
| SCHEMBL284309 | 0.69 | — | — | |
| SCHEMBL28318997 | 0.69 | — | — | |
| SCHEMBL28143225 | 0.69 | KDM4E (0.48) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| EP-2182801-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | Limerick BioPharma, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-10-15 | — | — | US | disclosed |
| WO-2009018320-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009018350-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | CYP11B2, CYP11B1, GLS2 | APP 1528/4885ADORA3 2658/4885ADORA2A 816/4885 |
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | CYP11B2, CYP11B1, GLS2 | APP 1528/4885ADORA3 2658/4885ADORA2A 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.